Happy Friday!
October is Dysautonomia Awareness Month. Dysautonomia is a collection of conditions that affect the autonomic nervous system. This can lead to a loss of control of the body’s “automatic” functions, such as blood pressure, digestion or pupil dilation. If you’d like to help spread awareness, Dysautonomia International has put together a great list of ways that you can bring attention to this rare condition.
In this weeks Editor’s Choice, we have details about Nucala, the first biologic approved to treat hypereosinophilic syndrome. We also have information from a National Institutes of Health study about post-exertional malaise in ME/CFS patients. And finally, can AI and machine learning help rare patients get diagnosed and treated faster? A new study helps shed some light on that question.
Nucala (Mepolizumab) Approved as HES Treatment
This approval is also meaningful as Nucala now becomes the first biologic approved to treat HES.
New NIH Study Explores PEM Symptoms in ME/CFS
In a recent groundbreaking study, patients with ME/CFS spoke directly about the difficulties of dealing with PEM.
Can AI and Machine Learning Help Rare Patients Get Diagnosed and Treated Faster?
In this study, machine learning identified patterns that were primary based on patient diagnoses, which procedures they had received, and what medicines they had been prescribed.
